CVSI — CV Sciences Income Statement
0.000.00%
Last trade - 00:00- $6.50m
- $5.43m
- $16.00m
- 75
- 97
- 57
- 90
Annual income statement for CV Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 53.7 | 24.4 | 20 | 16.2 | 16 |
| Cost of Revenue | |||||
| Gross Profit | 35.1 | 11 | 8.82 | 5.55 | 7.08 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 70.9 | 47 | 35.5 | 22.9 | 12.6 |
| Operating Profit | -17.2 | -22.6 | -15.5 | -6.72 | 3.36 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.2 | -22.6 | -15.6 | -8.26 | 3.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.6 | -22.3 | -15.6 | -8.21 | 3.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.6 | -22.3 | -15.6 | -8.21 | 3.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.6 | -22.3 | -15.6 | -9.13 | 3.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.17 | -0.223 | -0.126 | -0.061 | 0.021 |